Naser L. Rezk, PhD

OFFICE: KAIMRC HOME: **** Dawn Dr

National Guard Health Hurdle Mills, NC 27541

Riyadh, KSA 919-***-****

v4s65f@r.postjobfree.com 919-***-****

Phone 054******* v4s65f@r.postjobfree.com

Citizenship: American citizen

MISSION STATEMENT

I do believe that our responsibility is to prepare individuals for lives of intellectual, professional, and civic integrity, in which diversity and service to others are valued and practiced.

EDUCATION

2007 Doctor of Philosophy in Bioorganic Chemistry

Department of Biochemistry Chemistry

Tanta University Tanta, Egypt

Practical work course done at University of North Carolina Pharmacotherapy & Experimental Therapeutics, UNC, Chapel Hill, NC, USA

1994 Master of Science in Biochemistry

Department of Chemistry and Biochemistry

El-Menoufia University, El-Menoufia, Egypt

MS Thesis: “Determination of theophylline in different body fluids”

Thesis including; developing methodologies for Therapeutic Drug monitoring (TDM) of theophylline and other ethylated xanthenes in human body fluids (Blood Plasma, Saliva, and Urine).

1983 BS of Science in Chemistry

College of Sciences

El-Menoufia University, El-Menoufia, Egypt

All educational credentials have been evaluated through Evaluation of international educational credentials “American Association of Collegiate Registers and Admissions Officers (AACRAO) Washington DC, USA.

EXPERTISE

Over twenty-three years of research experience in; laboratory science, clinical pharmacology, pharmaceutical industry and medical technology fields, developing new technologies, validating research methodologies and strategically designed many successful research core laboratory facilities. In addition to analytical/ bioanalytical methods development, validation I structured a research team for applications in clinical pharmacology, drug formulation, drug quality control, therapeutic drug monitoring and biomedical research with world class level of strong background, research experience in AIDS treatment and HIV-prevention.

Design and operate research and services laboratories to adapt high technology;

i) To improve generic drugs,

ii) To increase research impact factor for international publications,

iii) Introduce scientific solutions for Pharma/Biophara and food industry by linking the academic institutes with industrial setting

iv) Improve and grow business oriented projects.

Design chromatography and mass spectrometry solutions suitable for industry and academia. Qualified speaker, and facilitator of professional communication and leader of fast growing organization. Strong interpersonal skills demonstrated with proven ability to collaborate effectively with individuals on all levels.

JOURNAL REVIEWER

1. Journal of Chromatography B. Biomedical sciences and applications (2003-Present).

2. Journal of Chromatography Symposium Volumes 2003.

3. Talanta, Fundamental theory and practice of analytical chemistry Journal (2003-Present).

4. JAOAC INTERNATIONAL (Journal of association of official chemists) Bioanalytical chemistry and Microbiological research. (2003-Present).

5. Journal of Pharmaceutical and Biomedical Analysis (2004-present)

6. Journal of Clinica Chemica Acata (2005-present)

7. Vaccine (2005-present)

8. Informa Health Care (2006-present)

9. Expert Opinion on Pharmacotherapy (2007-present)

10. Analytica Chimica Acta (2008-present)

11. Journal of Current Pharmaceutical Analysis (2008-present)

12. The Analyst RSC (2011)

JOURNAL EDITOR

o Journal of Analytical & Bioanalytical Techniques

HONORS AND AWARDS

o 2008: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2007: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2006: The State of North Carolina Governor Award of excellence for Innovation in Science.

-It is the highest honor that can be bestowed on a state level for service of the citizens of North Carolina

o 2006: University of North Carolina at Chapel Hill (UNC-CH) Chancellor Award of excellence for Innovation in Science.

-Recognizing works and efforts in establishing the first Clinical Pharmacology& Analytical Chemistry Core’s “top ranking laboratory core facility among similar units" nationally and internationally in matter of quality, quantity and revenue.

o 2006: Association of quality assessment in TDM and Clinical Toxicology Certificate (Diamond Level)

o 2005: Association of quality assessment in TDM and Clinical Toxicology Certificate (Gold Level)

o 2005: International toastmaster Award “Advanced Toastmaster”

o 2004: Association of quality assessment in TDM and Clinical Toxicology Certificate (Silver Level)

o 2003: International toastmaster Award “Competent Toastmaster”

o 2003: International toastmaster Award “Competent Leader”

TRAINEESHIP

Oct 1985 – Oct 1986 Medical Center

Medical technology training:

Hematology, Biochemistry (clinical biochemistry), Microbiology, Immunology and Serology

Jun 1996 – Jun 1997 Cannon Research Center

Medical technology training:

Clinical cytogenenetics

Dr. Frank Grass

PROFESSIONAL WORK

Nov 2010 – Present Associate Professor

King Saud bin Abdulaziz Medical Science University, Riyadh, KSA

Research Scientist (laboratory Director)

King Abdullah International Medical Research Center, Riyadh, KSA

Oct 2007 – Sep 2010 Research assistant professor

Director of Clinical Pharmacology and Analytical Chemistry Core facility (CPAC)

The department of pharmacotherapy and experimental therapeutics, School of Pharmacy

University of North Carolina at Chapel Hill

Chapel Hill, NC

Jan 2006 – Oct 2007 Research Associate (associate director)

UNC Center for Aids Research (CFAR) Clinical Pharmacology and Analytical Chemistry Core

University of North Carolina at Chapel Hill

Chapel Hill, NC

Sep 2004 – Jan 2006 Research Associate

School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics

3319 Kerr Hall, CB #7360

The University of North Carolina

Chapel Hill, North Carolina

27599-7360

May 2003– Oct 2007 Research Instructor

Clinical Pharmacology/Analytical Chemistry Core

UNC Center for AIDS Research,

The University of North Carolina

Chapel Hill, North Carolina

Mar 2002– Jul 2004 Research Scientist

ACTG Pharmacology at UNC

UNC AIDS Clinical Trials Unit (ACTG)

July 2002 – Jul 2003 Research Analyst

Pharmacotherapy and Experimental Therapeutics

School of Pharmacy, UNC-CH

Mar 2000 – Jul 2002 Research Specialist

UNC Center for AIDS Research

Clinical Pharmacology/Analytical Chemistry Core

University of North Carolina at Chapel Hill

Dr. ADM Kashuba and Dr. R Tidwell

Chapel Hill, North Carolina

27599-7360

May 1999 – Mar 2000 Research Scientist

Department of Chemical Discovery

Rhone Poulanc/Avantis RTP, NC

Dec 1998 – May 1999 Formulation Chemist

Department of Drug Development and Formulation

Trimeris Inc., Durham, NC

Dr. MC King

Feb 1998 – Jul 1998 Analytical Chemist

Department of Quality Control

Vintage Pharmaceutical Inc. Charlotte North Carolina,

J. Spincer

Dec 1996 – Feb 1998 Volunteer Scientist

Department of Clinical Genetics (Cytogenetics Laboratory)

Canon Research Center

Carolina Medical Center, Charlotte, NC

Jun 1990 – Dec 1994 Research Associate

Clinical Pharmacology Department

School of Medicine

El-Menoufia university, El-Menoufia, Egypt

PROFESSIONAL AFFILIATIONS

Professional Affiliation:

Fellow: Egyptian Chemical Society 1985-1996

Member: American Chemical Society (ASC)1996-Present

Advance for Medical Laboratory Professional 1996-Present

American Association for the Advancement of Science 1996-Present

Toastmaster International 2001-Present

American Association of Colleges of Pharmacy (AACP) 2008-Present.

GRANTS and CONTRACTS:

1. Kashuba ADM and Rezk, NL, Principal Investigators, Shimadzu LC/MS Grant for Academic Institutions. 07/2005. $65,000.00

2. Rezk, A H. Principal investigator, Kashuba ADM. Co-Investigator. University of North Carolina Tibotec Therapeutic. Drunavir cervicovaginal secretion study, 03/2008. $140,361.00

3. Rezk, A H. Principal investigator, Kashuab ADM. Co-Principal investigator. University of North Carolina Conrad “Bioanalytical methods development and validation of UC-781 in rabbit, Human and Monkey” 07/2008 $456,572 7

4. Rezk, A H. Principal investigator, Kashuab ADM. Co-Principal investigator. University of North Carolina Conrad amendment on “Bioanalytical methods development and validation of UC-781 in rabbit, Human and Monkey” 02/2009 $68,486

5. Rezk NL, Investigator. Antiretroviral Pharmacology in the Genital Tract. 4/03-2/08. K23 AI54980.

6. Rezk NL, Core Associate Director. General Clinical Research Center. 01/06 – 06/08. M01-RR00046.

7. Rezk, NL, Co-Investigator. The Effect Of Tipranavir/Ritonavir On Steady-State Concentrations Of Omeprazole And Its Metabolites. Boehringer Ingelheim Pharmaceuticals, Inc. 12/2006 – 2/2007. $51,100.00

8. Rezk, NL Co- Investigator, Evaluating the Effects of Tipranavir (with Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers. Boehringer Ingelheim Pharmaceuticals, Inc. (Investigator-Initiated Research) 2/2006 – 2/2007. $1,668,280.00

9. Rezk, NL, Co-Principal Investigator, Shimadzu LC/MS Grant for Academic Institutions. 07/2005. $65,000.00

10. Rezk, NL, Co-Principal investigator. Adult AIDS Clinical Trials Group. Clinical Pharmacology Support Laboratory. DAIDS (NIH). 1/2004-12/2005. $560,000.00

SELECTED PUPLICATIONS

1. Rezk NL, Development and validation of LC-ESI-MS method for sensitive, accurate and rapid determination of UC-781 in New Zealand white rabbit plasma, Talanta, 85 (2011) 2074

2. Choi SO, Rezk N, Kim JS, Kashuba AD, Develpoment of an LC-MS method for measuring TNF in Human Vaginal Tissue, J Chromatogr Sci. 48;3 (2010) 219-223.

3. Twigg HL, Schnizlein-Bick CT, Weiden M, Valentine F, Wheat J, Day RB, Rominger H, Zheng L, Collman RG, Coombs RW, Bucy RP, Rezk NL, Kashuba AD, Measurement of antiretroviral drugs in the lings of HIV-infected patients HIV Ther. Mar 1;4 ;2 (2010) 247-251.

4. Dumond JB, Vourvahis M, Rezk NL, Paterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuaba AD, A Phenotype-genotype approach to predicting CYP450 and P-glucoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir, Clin Pharmacol Ther. 87;6 (2010) 735-742.

5. Corbett AH, Hosseinipour MC, Nyrenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P, Pharmacokinetics of generic and trade formulations of lamivudine and nevirapine in HIV-infected Malawian children, Antivir Ther. 15;1 (2010) 83-90.

6. McRae M, Rezk NL, Bridges AS, Corbett AH, Tien HC, Brouwer KL, Kashuba AD, Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity, Pharmacotherapy, 30;1 (2010)17-24.

7. Talameh JA, Pharm D, Rezk NL, PhD, Kashuba DM, Pharm D, Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection J. Chromatoger B Analyt Technol Biomed Life Sci (2010) 1:878(1):92-6.

8. Paul Leger, MD, MPH, Rebecca Dillingham, MD, MPH, Carole Anne Beauharnais, MD, Angela D. M. Kashuba, PharmD, Naser L. Rezk, PhD, Daniel W.Fitzgerald, MD, Jean William Pape, MD, and David W. Haas, MD, Cyp2B6 Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port-au-Prince, Haiti, JID 200(2009) 955.

9. Rezk NL, White N, Jennings S, Kashuba A, A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma, Talanta,79 (2009)1372.

10. Shouhdary SK, Rezk NL, Ince LW. Cheema M, Zhang L, Su L, Swabstrom R, Kashuba DMA, Margolis D, Suppression of HIV-1 viremia with reverse transcriptase inhibitors, CD4* T Cell recovery, and viral rebound upon therapy interruption in a new model for HIV treatment in the humanized Rag2 -/- Уc -/- mice, J Virol. 83;16 (2009) 8254

11. Kwara A, Lartey M, Lartey M, Boamah I, Rezk NL, Court M., Oliver-Commey J, Kenu E, Kashuba A, Court M, Interindividual Variability in Pharmacokineticks of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian patients, JCP.(2009)

12. Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvagis M., Horton AL, Fiscus SA, Patterson KB, Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in HIV-1 infected Women, Antimicrob Agents Chemother, 2009

13. Choi SO, Rezk NL, Kim J. Kashuba ADM, Development of a LC-MS method for measuring TNF in human vaginal tissue. JCS 2009

14. Kwara A, Lartey M., Kwamena Sagoe, Rezk NL, Court M., CYP2B6 (c.516G T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. BJCP.2009

15. Rezk NL, White N, Kashuba A, An accurate and precise high performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal Chim Acta, 2008 Nov3:628(2):204-13

16. Rezk NL, White N, Bridges AS, Abdel-Megeed MF, Mohamed TM, Moselhy SS, Kashuba AD. Studies on Antiretroviral Drug Concentrations in Breast Milk: Validation of a Liquid Chromatography-Tandem Mass Spectrometric Method for the Determination of 7 Anti-Human Immunodeficiency Virus Medications Ther Drug Monit, 2008 Aug 27.

17. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.. PLoS Med. 2008 Aug 5;5(8):e157; discussion e157.

18. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, P, Rezk NL, Kashuba A, Anton P, McGowan, Shattock R, Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel, PLoS Medicine 2008 August 5;8: 165-167.

19. DiCenzo R, Peteson D, Cruttenden K, Mariuz P, Rezk NL, Hochreiter J, Gelbard H, Schifitto G. Effect of minocycline and valporic acid coadministration on atazanavir plasma concentrations in HIV-ifectd adults receiving atazanavir/Ritonavir, Antimicrob. Agents Chemother. 2008 Jun 23.

20. Tappouni A, Rublein JC, Donovan BJ, Hollowell SB, Tien HC, Min SS, Theodore D, Rezk NL, Smith PC, Tallman MN, Raasch RH, Kashuba AD. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir, Am J Health Syst Pharm. 2008 Mar 1:65 (5):422-128.

21. Kwara A, DeLong A, Rezk NL, Hogan J, Burtwell H, Champan S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, Kashuba A, Susan Cu-Uvin, Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women, Clin Infect Dis. 2008 Mar 1;46(5):719-25.

22. Vourvahis M, Tappouni H, Patterson K, Chen Y, Rezk NL, Fiscus S, Kearney B, Rooney J, Hui J, Cohen M, Kashuba A, Tenofovir Pharmacokinetics in the Genital Tract: Implication for Transmission Prevention, JAIDS,2008

23. Dumond J, Yeh R., Patterson K, Corbett A, Jung B, Rezk NL, Bridges A, Stewart P, Cohen M, Kashuba ADM, Antiretroviral Drug Exposure in the Female Genital Tract: Implications for Oral Pre-and Post-Exposure Prophylaxis, AIDS, 2007 Sep 12:21(14):1899-907.

24. Rezk NL, Abdel-Megeed M, Kashuba ADM. Development of a highly efficient extraction technique and specific multiplex assy for measuring drug concentrations in breast milk. Ther Drug Monit, 2007 Aug 29(24):429-36.

25. Jung BH, Rezk NL, Bridges AS, Kashuba ADM, Simultaneous determination of 16 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, 21;20 (2007) 1095.

26. Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, Van der Horst C, Kashuba ADM. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian subjects. AIDS, 21;1 (2007) 59-64.

27. Choi SO, Rezk NL, Kashuba ADM, High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications

J Pharm Biomed Anal. 43 ( 200*-****-****.

28. Rezk NL, Brown, K, Kashuba, ADM, A simple and sensitive bioanalytical assay for simultaneous quantitative determination of omeprazole and its three metabolites in human blood plasma using RP- HPLC after an optimized liquid-liquid extraction procedure. J Chromatogr B 2006; 5,844 (2);314-321.

29. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Klein C, Rublein J, Kashuba ADM. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes (CYP) 2C9, CYP2C19, and CYP1A2, but Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers. JAIDS 2006; 42:52-60.

30. Rezk N, Crutchley R, Yeh RF, Kashuba ADM. Full Validation of an Analytical Method For The HIV Protease Inhibitor Atazanavir In Combination With 8 Other Antiretroviral Agents and Its Applicability to Therapeutic Drug Monitoring. Ther Drug Monit, 2006 Aug;28(4):517-25.

31. Rezk NL, Crutchley RD, Kashuba ADM. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction, Journal of Chromatography B 2005; 822:201-208.

32. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba ADM. Protease inhibitor and Nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. J AIDS 2004; 37(5):1577-1580.

33. Rezk NL, Tidwell RR, Kashuba ADM. High-Performance Liquid Chromatography Assay For The Quantification Of HIV Protease Inhibitors And Non-Nucleoside Reverse Transcriptase Inhibitors In Human Plasma J Chromatogr B Analyt Technol Biomed Life Sci 2004;805(2):241-247.

34. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba ADM, The Pharmacokinetics, Safety, and Initial Virologic Response of A Triple-Protease Inhibitor Salvage Regimen Containing Amprenavir, Saquinavir, and Ritonavir, J Acquir Immune Defic Syndr 2004;36:921–928.

35. Rezk NL, Tidwell RR, Kashuba ADM. Simultaneous Determination of Six HIV Nucleoside Analogue Reverse Transcriptase Inhibitors and Nevirapine By Liquid Chromatography With Ultraviolet Detection After Solid-Phase Extraction. J Chromatogr B 2003; 791:137–147.

36. Rezk NL, Tidwell RR, Kashuba ADM. Simple and rapid quantification of the nonnucleoside reverse transciptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 2002; 774 (1);79-88.

SELECTED SCIENTIFIC ABSTRACTS:

1. Rezk NL, Innovation in method development; Drugs solubility and stability during bioanalysis process, 3ed World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit, March 26-28, 2012 Las Hyderabad, India.

2. Rezk NL, Bioanalytical laboratory design; Critical planning for 21st century Bioequivalence laboratory, 2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit, 06-08 June 2011 Las Vegas, USA

3. Corbett A., Martinson F., Rezk N, Kashuba A., Jamieson D., Chasela C., Kayira D., Tegha G., Kamwendo D., Van Der Horst C., The BAN Study Team. Lopinavir/Ritonavir Concentrations in Breast Milk and Breast-feeding infants. 16th Conference on Retroviruses and Opportunistic Infections Montréal, CA, Feb 2009.

4. Kawara A, Lartey M., Boamah I., Rezk N, Oliver-Commey J., Kenu E., Kashuba A., Court M., Variability in the pharmacokinetics of NRTI in TB/HIV Co-infected Patients. 16th Conference on Retroviruses and Opportunistic Infections Montréal, CA, Feb 2009.

5. Rezk NL, White N, Bridges A, Abdel-Megeed MF, Mohamed T, Moselhy S, Kashuba A, Innovation in Analytical Chemistry: Promoting the HIV Prevention and Treatment Agenda. BIT’s 1st Annual World Summit of Antiviral, Kunming, China July 2008.

6. Schwartz J, Kashuba A, Rezk N, Nasution M, Choi SO, Kim JS, Brache V, Poindexter A, Creinin M, Ju S, Cochon L, Taylor D, Mauck C. Preliminary results from a pharmacokinetic study of the candidate vaginal microbicide agent 1% tenofovir gel, American society for clinical pharmacology and therapeutics annual meeting, Orlando,FL, 2-5 April 2008.

7. K. Ilic, G. Hogeland, N. Rezk, N. White, J. Lamba, C. Lee, ADM. Kashuba, EG. Schuetz, CM. Lindley, ML. Chen, RL. Hawke, The influence of sex, race/ethnicity and CYP 2B6 genotype on bupropion (B) metabolism. American society for clinical pharmacology and therapeutics annual meeting, Orlando,FL, 2-5 April 2008.

8. Kevin C Brown, Mina C Hosseinipour, Janelle M Hoskins, Haiaso-Chuan Tien, Rezk NL., Peter Kazemba, Ralf Weigel, Howard L Mcleod, Angela DM Kahsuba, Amanda H Corbett. Correlations between Drug Metabolizing Enzyme and Drug Transporter Genotypes and Nivirapine Eposure in HIV-Infected Malawian Adults and Childeren.Antiretroviral Drug Concentrations in Breast Milk and Breastfeeding Infants., 9th International workshop of clinical pharmacology of HIV, NewOrleans , April 2008

9. Corbett A., Kashuba A., Rezk NL., Jamieson D, Chasela C., Hyde L., Yusuf Ahmed Y., Tegha G., Joaki G, Kamwendo D, van der Horst C., and the BAN Study Team. Antiretroviral Drug Concentrations in Breast Milk and Breastfeeding Infants. 15th Conference on Retroviruses and Opportunistic Infections Boston, MA, Feb 2008.

10. Vourvahis, M, Dumond J, Patterson K, Rezk N, Hsiao T, Li J, Choi S, White N, Drulak M, Sabo J, Castles M, MacGregor T, Kashuba A. Effects of Tipranavir/ritonavir (TPV/r) on the Activity of Cytochrome P450 (CYP) Enzymes 1A2, 2C9, and 2D6 in healthy Volunteers. 8th International workshop of clinical pharmacology of HIV, Budapest, April 2007

11. Vourvahis, M, Dumond J, Patterson K, Rezk N, White N, Jennings S, Tien H, Sabo J, MacGregor T, Kashuba A. Effects of Tipranavir/ritonavir (TPV/r) on the Activity of Hepatic and Intestinal Cytochrome P450 3A4/5 and P-glycoprotein (Pgp): Implications for Drug Interaction. Abstr L-150. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007.

12. Cu-Uvin S, DeLong A, Rezk N, Jogan J, Burtwell H, Chapman S, Moreira C, Kurpewski J, Ingersoll J, Caliendo A, Kashuba A. Antiretroviral Drug Concentrations in the Genital tract of HIV-Infected Women. Poster # 778. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles, CA, Feb 2007

13. Dumond J, Yeh R, Patterson K, Corbett A, Jung BH, Rezk N, Bridges A, Dempsey E, Cohen M, Kashuba ADM. First Dose and Steady-State Genital Tract Pharmacokinetics of Ten Antiretroviral Drugs in HIV-Infected Women: Implications for Pre- and Post-Exposure Prophylaxis 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, Feb 2006

14. Vourvahis M, Tappouni H, Patterson K, Chen YC, Rezk N, Fiscus S, Kearney BP, Rooney JF, Cohen MS, Kashuba ADM. A Pharmacologic Basis for the Use of Tenofovir In Pre- and Post-Exposure Prophylaxis: Intra and Extracellular Genital Tract Pharmacokinetics and Pharmacodynamics from First Dose to Steady State in HIV-1 Infected Men and Women 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, Feb 2006

15. Corbett A, Mosseinipour M, Nyirenda J, Kanyama C, Mshali I, Chinyama S, Lyke A, Rezk N, Tien H, Hoffman I, Kashuba A, Mwansambo C, Weigel R, Kazembe P. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine, and nevirapine in HIV-infected Malawian Children. 2005 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract #H-1106

16. Yeh RF, Gaver VE, Park JJ, Patterson KB, Rezk N, Baxter-Meheux F, White N, Eron JJ, Klein CE, Rublein J, Kashuba ADM. Lopinavir/ritonavir inhibits intestinal CYP3A Activity to a Greater Extent than Hepatic CYP3A activity Using Midazolam as a Biomarker in Healthy Human Volunteers. 6th International Workshop on Clinical Pharmacology in HIV Therapy. Quebec City, Quebec, April 2005.

17. Hosseinipour M, Corbett A, Kanyama C, Mshali I, Chinyama S, Phakati S, Rezk N, White S, Van der Horst C, Kashuba ADM. Pharmacokinetic Comparison of Generic and Trade Formulations of Lamivudine, Stavudine and Nevirapine in 12 HIV-Infected Malawian Subjects. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005.

18. Lima AM, Brito LFB, Leite RD, Lima NL, Kashuba ADM, Rezk NL, Bushen OY, Dilingham RD, Gurrant R. Glutamine and alanyl-glutamine enhance absorptive function in malnourished children and HIV patients. 42nd Annual Meeting Infectious Disease Society of America. Boston, MA. September 2004.

19. Kashuba ADM, Min SS, Corbett AH, Rezk N, Cohen MS. Comparison of Protease Inhibitor and Non-Nucleoside Reverse Transcriptase Inhibitor Concentrations in the Male and Female Genital Tract. Journal of Investigative Medicine 2003; 51 (2).

20. Corbett A, Eron J, Diebold M, Fiscus S, Rezk N, Kashuba A. Short-term Safety and Efficacy of An Amprenavir [APV] /Saquinavir [SQV] /Ritonavir [RTV] Salvage Regimen. Infectious Diseases Society of America. Chicago, IL, 2002.

21. Min SS, Corbett AH, Rezk N, Fiscus SA, Cohen MS, Kashuba ADM. Differential Penetration of Protease Inhibitors [PI] and Non-Nucleoside Reverse Transcriptase Inhibitors [NNRTI] into the Female Genital Tract [GT] World AIDS Conference, Barcelona, Spain 2002.

22. Corbett A, Eron J, Diebold M, Rezk N, Troiani L, Kashuba ADM. A Triple Protease Inhibitor [PI] Salvage Regimen of Amprenavir [APV] + Saquinavir [SQV] + Ritonavir [RTV]: Steady State [SS] Pharmacokinetics [PK] and Initial RNA and CD4 Response. World AIDS Conference, Barcelona, Spain 2002.

23. Kashuba ADM, Min SS, Corbett AH, Rezk N, Cohen MS. Comparison of Protease Inhibitor [PI] and Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI] Concentrations [CONC] in the Male [M] and Female [F] Genital Tract [GT]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington DC 2002.

WEB SCIENTIFIC& TECHNICAL ARTICLES:

1- Naser L. RezkPhD, SPE-HPLC method for HIV integrase inhibitors, Separation Science, (2008).

http://www.sepscience.com/News/SPE-HPLC-method-for-HIV-integrase-inhibitors.aspx

2- Naser Rezk, PhD and Angela Kashuba, Pharmacology of prevention ( new scientific field)

http://cfar-code.unc.edu/Newsletters/Volume%202,%20Issue%201.pdf

3- Naser Rezk, PhD, UC781 analysis for HIV-Prevention in Advanced Engineering (2012)

http://advancesinengineering.com/chemical-engineering/development-and-validation-of-lc-esi-ms-method-for-sensitive-accurate-and-rapid-determination-of-uc-781-in-new-zealand-white-rabbit-plasma/

SELECTED PRESENTATIONS:

1. Innovation in method development; Drugs solubility and stability during bioanalysis process, 3ed World Congress on Bioavailability& Bioequivalence: Pharmaceutical R&D Summit, March 26-28, 2012 Las Hyderabad, India.

2. Bioanalytical laboratory design; Critical planning for 21st century Bioequivalence laboratory, 2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R&D Summit, 06-08 June 2011 Las Vegas, USA.

3. “Innovation in Analytical Chemistry to promote the HIV Prevention and Treatment Agenda” BIT’s 1st Annual World Summit of Antiviral, Kunming, China, July, 2008.

4. “Determination of Drug Concentrations in Human Breast Milk” CFAR Seminar Series, School of Medicine, UNC, Chapel Hill May, 2007.

5. “Quantification of Antiretroviral Medication in Human Breast Milk” Pharmacotherapy & Experimental Therapeutics Seminar Series, School of Pharmacy, UNC, Chapel Hill September, 2006.

6. “Bioanalytical Method Development Column Selection and Innovation” Clinical Pharmacology and Analytical Chemistry Laboratory Research group meeting, School of Pharmacy, UNC, Chapel Hill, Jun, 2006.

7. “Quality Assurance/Quality Control and Good Clinical Laboratory Practice GCLP ”Clinical Pharmacology and Analytical Chemistry Laboratory Research group meeting, School of Pharmacy, UNC, Chapel Hill, March 2005.

8. “Biomedical Assay Validation, Theory and Laboratory Practice” Pharmacotherapy& Experimental Therapeutics Seminar Series, School of Pharmacy, UNC, Chapel Hill, March 2004.

Contact this candidate